Ergene U.Ozbalci D.2024-07-222024-07-22201318781683http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/17279Imatinib mesylate selectively inhibits bcr/abl and other non-specific tyrosine kinases, such as c-kit and platelet derived growth factor (PDGF) receptor and successfully used to treat chronic myeloid leukaemia (CML). In most cases, the drug is well tolerated: however, side effects can be seen. Hair loss and paronychia inflammation were often reported with Imatinib, but total alopecia was rarely mentioned. We report a CML patient who was presented with alopecia and paronychia inflammation probably induced by imatinib therapy. We have successfully treated our patient by cessation and then re-applying therapy with lower doses after improvement of lesions and have not found a similar report in literature. © 2013 Elsevier Ltd.EnglishAlopeciaBenzamidesHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleMiddle AgedNecrosisParonychiaPiperazinesPyrimidinesimatinibmometasone furoatesteroidadultalopeciaarticlecancer chemotherapycase reportchronic myeloid leukemiacorticosteroid therapydiarrheadrug eruptiondrug withdrawaleosinophiliahumanhuman tissuemalenail diseasenail necrosisnephrectomyorbit edemapoliomyelitisskin biopsyskin necrosissteroid therapyArticle10.1016/j.transci.2013.01.002